|
1
|
Wolfgang CL, Herman JM, Laheru DA, Klein
AP, Erdek MA, Fishman EK and Hruban RH: Recent progress in
pancreatic cancer. CA Cancer J Clin. 63:318–348. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hurton S, MacDonald F, Porter G, Walsh M
and Molinari M: The current state of pancreatic cancer in Canada:
Incidence, mortality, and surgical therapy. Pancreas. 43:879–885.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Miwa T, Kokuryo T, Yokoyama Y, Yamaguchi J
and Nagino M: Therapeutic potential of targeting protein for Xklp2
silencing for pancreatic cancer. Cancer Med. 4:1091–1100. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zuo J, Zhang C, Ren C, Pang D, Li Y, Xie
X, Tang Z and Jiang X: Secretory leukocyte protease inhibitor is a
proliferation and survival factor for pancreatic cancer cells. Clin
Transl Oncol. 17:314–321. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Funel N, Del Chiaro M, Cahen DL and
Laukkarinen J: Pancreatic cancer. Gastroenterol Res Pract.
2015:8090362015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Thota R, Pauff JM and Berlin JD: Treatment
of metastatic pancreatic adenocarcinoma: A review. Oncology
(Williston Park). 28:70–74. 2014.PubMed/NCBI
|
|
8
|
Oettle H, Post S, Neuhaus P, Gellert K,
Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C,
et al: Adjuvant chemotherapy with gemcitabine vs observation in
patients undergoing curative-intent resection of pancreatic cancer:
A randomized controlled trial. JAMA. 297:267–277. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Burris HA III, Moore MJ, Andersen J, Green
MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo
AM, Tarassoff P, et al: Improvements in survival and clinical
benefit with gemcitabine as first-line therapy for patients with
advanced pancreas cancer: A randomized trial. J Clin Oncol.
15:2403–2413. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tempero MA, Behrman S, Ben-Josef E, Benson
AB III, Cameron JL, Casper ES, Hoffman JP, Karl RC, Kim P, Koh WJ,
et al: Pancreatic adenocarcinoma: Clinical Practice Guidelines in
Oncology. J Natl Compr Canc Netw. 3:598–626. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Oettle H and Riess H: Gemcitabine in
combination with 5-fluorouracil with or without folinic acid in the
treatment of pancreatic cancer. Cancer. 95:912–922. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Poplin E, Feng Y, Berlin J, Rothenberg ML,
Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalano P,
et al: Phase III, randomized study of gemcitabine and oxaliplatin
versus gemcitabine (fixed-dose rate infusion) compared with
gemcitabine (30-minute infusion) in patients with pancreatic
carcinoma E6201: A trial of the Eastern Cooperative Oncology Group.
J Clin Oncol. 27:3778–3785. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Colucci G, Labianca R, Di Costanzo F,
Gebbia V, Cartenì G, Massidda B, Dapretto E, Manzione L, Piazza E,
Sannicolò M, et al: Randomized phase III trial of gemcitabine plus
cisplatin compared with single-agent gemcitabine as first-line
treatment of patients with advanced pancreatic cancer: The GIP-1
study. J Clin Oncol. 28:1645–1651. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chauffert B, Mornex F, Bonnetain F,
Rougier P, Mariette C, Bouché O, Bosset JF, Aparicio T, Mineur L,
Azzedine A, et al: Phase III trial comparing intensive induction
chemoradiotherapy (60 Gy, infusional 5-FU and intermittent
cisplatin) followed by maintenance gemcitabine with gemcitabine
alone for locally advanced unresectable pancreatic cancer.
Definitive results of the 2000–01 FFCD/SFRO study. Ann Oncol.
19:1592–1599. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Philip PA, Benedetti J, Corless CL, Wong
R, O'Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC,
Rivkin SE, et al: Phase III study comparing gemcitabine plus
cetuximab versus gemcitabine in patients with advanced pancreatic
adenocarcinoma: Southwest Oncology Group-directed intergroup trial
S0205. J Clin Oncol. 28:3605–3610. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Minami K, Shinsato Y, Yamamoto M,
Takahashi H, Zhang S, Nishizawa Y, Tabata S, Ikeda R, Kawahara K,
Tsujikawa K, et al: Ribonucleotide reductase is an effective target
to overcome gemcitabine resistance in gemcitabine-resistant
pancreatic cancer cells with dual resistant factors. J Pharmacol
Sci. 127:319–325. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cohen PT: Novel protein serine/threonine
phosphatases: Variety is the spice of life. Trends Biochem Sci.
22:245–251. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cohen PT, Brewis ND, Hughes V and Mann DJ:
Protein serine/threonine phosphatases; an expanding family. FEBS
Lett. 268:355–359. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Morita K, Saitoh M, Tobiume K, Matsuura H,
Enomoto S, Nishitoh H and Ichijo H: Negative feedback regulation of
ASK1 by protein phosphatase 5 (PP5) in response to oxidative
stress. EMBO J. 20:6028–6036. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Douglas P, Moorhead GB, Ye R and
Lees-Miller SP: Protein phosphatases regulate DNA-dependent protein
kinase activity. J Biol Chem. 276:18992–18998. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
von Kriegsheim A, Pitt A, Grindlay GJ,
Kolch W and Dhillon AS: Regulation of the Raf-MEK-ERK pathway by
protein phosphatase 5. Nat Cell Biol. 8:1011–1016. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yong WH, Ueki K, Chou D, Reeves SA, von
Deimling A, Gusella JF, Mohrenweiser HW, Buckler AJ and Louis DN:
Cloning of a highly conserved human protein serine-threonine
phosphatase gene from the glioma candidate region on chromosome
19q13.3. Genomics. 29:533–536. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang J, Roe SM, Cliff MJ, Williams MA,
Ladbury JE, Cohen PT and Barford D: Molecular basis for TPR
domain-mediated regulation of protein phosphatase 5. EMBO J.
24:1–10. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hinds TD Jr and Sánchez ER: Protein
phosphatase 5. Int J Biochem Cell Biol. 40:2358–2362. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chinkers M: Protein phosphatase 5 in
signal transduction. Trends Endocrinol Metab. 12:28–32. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Golden T, Swingle M and Honkanen RE: The
role of serine/threonine protein phosphatase type 5 (PP5) in the
regulation of stress-induced signaling networks and cancer. Cancer
Metastasis Rev. 27:169–178. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Swingle MR, Honkanen RE and Ciszak EM:
Structural basis for the catalytic activity of human
serine/threonine protein phosphatase-5. J Biol Chem.
279:33992–33999. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zuo Z, Dean NM and Honkanen RE:
Serine/threonine protein phosphatase type 5 acts upstream of p53 to
regulate the induction of p21(WAF1/Cip1) and mediate growth arrest.
J Biol Chem. 273:12250–12258. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao S and Sancar A: Human blue-light
photoreceptor hCRY2 specifically interacts with protein
serine/threonine phosphatase 5 and modulates its activity.
Photochem Photobiol. 66:727–731. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yamaguchi Y, Katoh H, Mori K and Negishi
M: Galpha(12) and Galpha(13) interact with Ser/Thr protein
phosphatase type 5 and stimulate its phosphatase activity. Curr
Biol. 12:1353–1358. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chatterjee A, Wang L, Armstrong DL and
Rossie S: Activated Rac1 GTPase translocates protein phosphatase 5
to the cell membrane and stimulates phosphatase activity in vitro.
J Biol Chem. 285:3872–3882. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hattori K, Naguro I, Runchel C and Ichijo
H: The roles of ASK family proteins in stress responses and
diseases. Cell Commun Signal. 7:92009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zheng X, Zhang L, Jin B, Zhang F, Zhang D
and Cui L: Knockdown of protein phosphatase 5 inhibits ovarian
cancer growth in vitro. Oncol Lett. 11:168–172. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhi X, Zhang H, He C, Wei Y, Bian L and Li
G: Serine/threonine protein phosphatase-5 accelerates cell growth
and migration in human glioma. Cell Mol Neurobiol. 35:669–677.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Feng L, Sun P, Li Z, Liu M and Sun S:
Knockdown of PPP5C inhibits growth of hepatocellular carcinoma
cells in vitro. Appl Biochem Biotechnol. 175:526–534. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu F, Iqbal K, Grundke-Iqbal I, Rossie S
and Gong CX: Dephosphorylation of tau by protein phosphatase 5:
Impairment in Alzheimer's disease. J Biol Chem. 280:1790–1796.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-(delta delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gottesman MM: Mechanisms of cancer drug
resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Moore MJ, Goldstein D, Hamm J, Figer A,
Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al:
Erlotinib plus gemcitabine compared with gemcitabine alone in
patients with advanced pancreatic cancer: A phase III trial of the
National Cancer Institute of Canada Clinical Trials Group. J Clin
Oncol. 25:1960–1966. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Huang P, Chubb S, Hertel LW, Grindey GB
and Plunkett W: Action of 2′,2′-difluorodeoxycytidine on DNA
synthesis. Cancer Res. 51:6110–6117. 1991.PubMed/NCBI
|
|
41
|
Li L and Leung PS: Use of herbal medicines
and natural products: An alternative approach to overcoming the
apoptotic resistance of pancreatic cancer. Int J Biochem Cell Biol.
53:224–236. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Golden T, Aragon IV, Zhou G, Cooper SR,
Dean NM and Honkanen RE: Constitutive over expression of
serine/threonine protein phosphatase 5 (PP5) augments
estrogen-dependent tumor growth in mice. Cancer Lett. 215:95–100.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Amable L, Grankvist N, Largen JW, Ortsäter
H, Sjöholm Å and Honkanen RE: Disruption of serine/threonine
protein phosphatase 5 (PP5:PPP5c) in mice reveals a novel role for
PP5 in the regulation of ultraviolet light-induced phosphorylation
of serine/threonine protein kinase Chk1 (CHEK1). J Biol Chem.
286:40413–40422. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jeong JY, Johns J, Sinclair C, Park JM and
Rossie S: Characterization of Saccharomyces cerevisiae protein
Ser/Thr phosphatase T1 and comparison to its mammalian homolog PP5.
BMC Cell Biol. 4:32003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Golden T, Aragon IV, Rutland B, Tucker JA,
Shevde LA, Samant RS, Zhou G, Amable L, Skarra D and Honkanen RE:
Elevated levels of Ser/Thr protein phosphatase 5 (PP5) in human
breast cancer. Biochim Biophys Acta. 1782:259–270. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shirato H, Shima H, Nakagama H, Fukuda H,
Watanabe Y, Ogawa K, Matsuda Y and Kikuchi K: Expression in
hepatomas and chromosomal localization of rat protein phosphatase 5
gene. Int J Oncol. 17:909–912. 2000.PubMed/NCBI
|
|
47
|
Ghobrial IM, McCormick DJ, Kaufmann SH,
Leontovich AA, Loegering DA, Dai NT, Krajnik KL, Stenson MJ, Melhem
MF, Novak AJ, et al: Proteomic analysis of mantle-cell lymphoma by
protein microarray. Blood. 105:3722–3730. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhou G, Golden T, Aragon IV and Honkanen
RE: Ser/Thr protein phosphatase 5 inactivates hypoxia-induced
activation of an apoptosis signal-regulating kinase 1/MKK-4/JNK
signaling cascade. J Biol Chem. 279:46595–46605. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Huang S, Shu L, Dilling MB, Easton J,
Harwood FC, Ichijo H and Houghton PJ: Sustained activation of the
JNK cascade and rapamycin-induced apoptosis are suppressed by
p53/p21(Cip1). Mol Cell. 11:1491–1501. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Michels J, Obrist F, Castedo M, Vitale I
and Kroemer G: PARP and other prospective targets for poisoning
cancer cell metabolism. Biochem Pharmacol. 92:164–171. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hong MY, Gao JL, Cui JZ, Wang KJ, Tian YX,
Li R, Wang HT and Wang H: Effect of c-Jun NH2-terminal
kinase-mediated p53 expression on neuron autophagy following
traumatic brain injury in rats. Chin Med J (Engl). 125:2019–2024.
2012.PubMed/NCBI
|
|
52
|
Bu HQ, Liu DL, Wei WT, Chen L, Huang H, Li
Y and Cui JH: Oridonin induces apoptosis in SW1990 pancreatic
cancer cells via p53- and caspase-dependent induction of p38 MAPK.
Oncol Rep. 31:975–982. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Harris SL and Levine AJ: The p53 pathway:
Positive and negative feedback loops. Oncogene. 24:2899–2908. 2005.
View Article : Google Scholar : PubMed/NCBI
|
